Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorcaserin and XR-Naltrexone for Opioid Use Disorder
NCT03169816Phase 3Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- May 2017
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lorcaserin in opioid use disorder (OUD), sponsored by New York State Psychiatric Institute. Primary endpoint: Proportion of Patients Successfully Inducted to Receive Naltrexone Injection at 1 week. Started May 2017; status: completed.
02
Drugs
lorcaserin
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT03169816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03169816.